1. Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives;Oshiro;J. Med. Chem.,1998
2. Perry: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder;Tracy, Swainston, Harrison;Review. Drugs,2004
3. US FDA, Center for Drug Evaluation and Research, Drug Approvals information, Available from URL: http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm; [Application No.: 21–436 Approval Date: 11/15/2002]
4. PMDA information, Available from URL: http://www.info.pmda.go.jp/shinyaku/g0601.html [Summary of Application Data; 2.6 Nonclinical, Pharmacokinetics].
5. Influence of Itraconazole Co-administration and CYP2D6 Genotype on the Pharmacokinetics of the New Antipsychotic ARIPIPRAZOLE;Kubo;Drug Metab. Pharmacokinet.,2005